Over the past year, the food allergy world has seen some truly exciting momentum—from new treatment approaches to innovative ways to deliver life-saving epinephrine. One breakthrough that has sparked a lot of conversation is the first FDA-approved epinephrine nasal spray, offering the first needle-free option for emergency allergic reactions.We’re thrilled to welcome someone at the center of this innovation: Rich Lowenthal, Co-founder, President, and CEO of ARS Pharma—the company behind neffy®. Rich joins us to give an inside look at neffy’s milestone year, what’s ahead for this new treatment option, and how ARS Pharma’s 'Get neffy® on Us Program' is helping expand access for families nationwide.Resources to keep you in the know:Get neffy® On Usneffy®neffy® in SchoolsARS PharmaYou can find FAACT's Roundtable Podcast on Apple Podcasts, Pandora, Spotify, Podbay, iHeart Radio, or wherever you listen to podcasts.Follow us on Facebook, Instagram, BlueSky, Threads, LinkedIn, Pinterest, TikTok, and YouTube.Sponsored by: ARS PharmaThanks for listening! FAACT invites you to discover more exciting food allergy resources at FoodAllergyAwareness.org!

Ver todos los episodios